Merck KGaA has announced that it will sell its Crop BioScience business to Danish company Novozymes A/S for $275 million.
Merck KGaA has announced that it will sell its Crop BioScience business to Danish company Novozymes A/S for $275 million.
Merck’s divested Crop BioScience business researches, develops and commercializes technologies used to improve plant health and crop yields. These activities are carried out in North and South America through EMD Crop BioScience, Milwaukee, USA; EMD Crop BioScience Canada; and Merck Crop BioScience Argentina.
“With the acquisition of Millipore the strategic focus of Merck’s chemicals business significantly changed towards the life science industries. The Crop BioScience business is focused on a specific segment within the agricultural industry and has very limited overlap with other parts of Merck’s business,” said Bernd Reckmann, member of the executive board of Merck in a statement.
“The acquisition of Crop BioScience strengthens our global position in the growing industry for agricultural biologicals providing products that enhance the natural growth and yield of crops,” said Steen Riisgaard, CEO of Novozymes. “We have found in Crop BioScience a company that has a strong strategic fit with our existing BioAg business.”
For more information visit www.novozymes.com and www.merck.de
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.